Local oestrogens vs systemic HRT: The one question every menopausal woman should ask before starting treatment

Local oestrogens vs systemic HRT: which one is right for you in menopause?

When menopause arrives, so do questions — and often confusion — about treatments. One of the most common is: “Should I use local oestrogens or systemic hormone replacement therapy (HRT)?” The short answer is: they are not interchangeable. They treat different problems, work in different ways and are chosen for different reasons. Here’s a clear, practical guide to help you understand the difference and decide what’s best for your symptoms and lifestyle.

What local oestrogens do — and when they shine

Local oestrogens are applied directly to the vulvo‑vaginal area (creams, pessaries, vaginal tablets or rings). Their effect is focused on the tissues of the vagina and lower urinary tract. These treatments are designed to relieve symptoms such as:

  • vaginal dryness
  • burning or irritation
  • pain during sex (superficial dyspareunia)
  • recurrent local infections
  • lower urinary tract symptoms linked to menopause (urgency, frequency)
  • Because they act locally, systemic absorption is minimal with most low‑dose formulations, which is why many women and clinicians see local oestrogens as a targeted and generally well‑tolerated option for urogenital symptoms.

    Local oestrogens are not all the same

    Two common types are estradiol (more potent) and estriol (milder, often with a predominately local effect). Choice depends on symptom severity, age, medical history and individual response. It’s important to know that a “vaginal oestrogen” label covers many products with different potencies and dosing schedules.

    Why local treatment sometimes isn’t enough

    Many women report a significant improvement with local oestrogens — improved lubrication, less burning and better tissue elasticity. Yet some still experience persistent pain at the vaginal opening. This is because the distribution of hormone receptors and nerve fibres varies across the vulvo‑vaginal area:

  • Inside the vaginal canal oestrogen receptors predominate and local oestrogens work well.
  • At the introitus and vestibule there are more androgen receptors and a higher density of nociceptive (pain) fibres.
  • This means that pain at the entrance of the vagina can have a different biological basis from deeper vaginal atrophy. In some cases additional approaches — such as local androgen support, pelvic physiotherapy, topical anaesthetics or multimodal treatment — may be necessary.

    What systemic HRT treats — and who it’s for

    Systemic HRT is designed to act across the whole body and is usually prescribed for broader menopausal symptoms such as:

  • hot flashes and night sweats
  • sleep disturbances
  • brain fog and mood changes
  • joint aches related to menopause
  • in selected women, bone protection
  • Systemic HRT is delivered orally, transdermally (patch or gel) or by other systemic routes. It addresses the systemic deficiency of oestrogen and can transform quality of life for women with generalized, severe symptoms. But it requires careful individual assessment because of potential contraindications and risks (history of thromboembolism, certain cancers, cardiovascular disease).

    They are often complementary — not competitive

    The key point is that local oestrogens and systemic HRT answer different clinical questions. A woman may only need local treatment for isolated genital symptoms. Another may need systemic HRT for disabling hot flushes. Many women on systemic HRT still benefit from additional local therapy to optimise vaginal health — because systemic HRT does not always give full relief at the tissue level for everyone.

    How the decision is made

    Choosing between local and systemic therapy is not about what is “stronger” but what is appropriate for the symptom profile and the individual. Important considerations include:

  • Which symptoms bother you most and how much they impact daily life
  • Your age and years since menopause
  • Personal and family medical history (cardiovascular risk, breast cancer, clotting disorders)
  • Any contraindications or precautions
  • Your clinician should explain the pros and cons, expected timelines of improvement and how to combine treatments if needed.

    Practical tips for discussing options with your clinician

  • Describe your symptoms specifically — dryness, burning, pain, leaks, hot flushes, sleep issues — and how they affect you.
  • Ask about the type of local oestrogen proposed and its expected systemic absorption.
  • If systemic HRT is suggested, discuss route (patch vs tablet) — patches typically have lower clotting risk.
  • Discuss follow‑up: how long before benefits are reassessed and how side effects will be monitored.
  • Remember the role of multimodal care

    Vulvo‑vaginal health is rarely dictated by a single hormone. A combined approach often works best: local oestrogens to rebuild tissues, physiotherapy for pelvic floor dysfunction, lubricants and moisturisers for immediate relief, and systemic HRT for broader menopausal symptoms where indicated. For persistent entry pain, consider evaluation for vestibulodynia and targeted treatments, including consideration of androgen support where appropriate.

    Empowerment and informed choice

    The most empowering question to ask is not “Which is better?” but “What problem am I trying to solve?”. A personalised approach — matching treatment to symptoms, history and goals — leads to better outcomes. Women deserve clear information: local oestrogens are excellent for urogenital symptoms, systemic HRT is for whole‑body menopausal changes, and both can be part of a tailored care plan to preserve comfort, sexuality and quality of life.

    Exit mobile version